Genentech/Roche’s Faricimab Phase 3 Program Fully Recruited with Enrollment Completion of Wet AMD Clinical Trials

Genentech and Roche have completed patient enrollment in the TENAYA and LUCERNE phase 3 clinical trials investigating faricimab for the treatment of wet age-related macular degeneration (AMD). The phase 3 YOSEMITE and RHINE diabetic macular edema (DME) clinical trials completed patient enrollment in September 2019. With these milestones, Genentech and Roche are ending 2019 having fully recruited the current faricimab phase 3 clinical trial program, comprised of more than 3,000 patients in two diseases, ahead of schedule.

Faricimab is the first bispecific antibody designed specifically for the treatment of retinal diseases. This investigational medicine simultaneously binds to and neutralizes Angiopoietin-2 (Ang2) and vascular endothelial growth factor A (VEGF-A). By targeting both Ang2 and VEGF-A, faricimab may lead to improved and sustained efficacy at longer treatment intervals, thereby delivering better vision outcomes for patients.

“Genentech remains committed to researching and developing new treatments for people living with wet AMD and other vision-threatening diseases,” Christopher Brittain, MBBS, BSc, MBA, MRCOphth, Vice President and Global Head of Genentech’s Ophthalmology Clinical Development program, said in a company statement. “The impact of wet AMD and DME on patients, their families and caregivers is one of the reasons Genentech and Roche are dedicated to bringing novel treatments to patients. We are so thankful to these patients and investigators for participating in these trials and we are proud to have fully recruited the faricimab Phase III program well ahead of schedule.”